

Variant: *NM\_000070.3(CAPN3):c.1194-2A>G*

Version: 1.0

[CA391999297](#)

[973317 \(ClinVar\)](#)

**Gene:** CAPN3 ([HGNC:825](#))

**Condition:** autosomal recessive limb-girdle muscular dystrophy ([MONDO:0015152](#))

**Inheritance Mode:** Autosomal recessive inheritance

**UUID:** 8811edc5-3569-4a44-8bc0-c60e7ab6a0d9

**Approved on:** 2025-10-09

**Published on:** 2025-11-11

### *HGVS expressions*

**NM\_000070.3:c.1194-2A>G**

NM\_000070.3(CAPN3):c.1194-2A>G

NC\_000015.10:g.42399490A>G

CM000677.2:g.42399490A>G

NC\_000015.9:g.42691688A>G

CM000677.1:g.42691688A>G

NC\_000015.8:g.40478980A>G

NG\_008660.1:g.56388A>G

ENST00000349748.8:c.1050-2A>G

ENST00000357568.8:c.1194-2A>G

ENST00000397163.8:c.1194-2A>G

ENST00000466369.5:n.1703-2A>G

ENST00000483208.5:n.1425-2A>G

ENST00000495723.1:n.1425-2A>G

ENST00000549793.5:n.1425-2A>G

ENST00000638141.2:n.1065-2A>G

ENST00000673658.1:n.178-2A>G

ENST00000673705.1:c.149-2A>G

ENST00000318023.11:c.1050-2A>G

ENST00000349748.7:c.1050-2A>G

ENST00000357568.7:c.1194-2A>G

ENST00000397163.7:c.1194-2A>G

NM\_000070.2:c.1194-2A>G

NM\_024344.1:c.1194-2A>G

NM\_173087.1:c.1050-2A>G

NM\_024344.2:c.1194-2A>G

NM\_173087.2:c.1050-2A>G

**Pathogenic**

**Met criteria codes** **5**

**PM3** **PS2\_Supporting** **PP4\_Strong**

**PVS1** **PM2\_Supporting**

**Not Met criteria codes** **1**

**PS1**

Expert Panel

[Limb Girdle Muscular Dystrophy VCEP](#)

Criteria Specification Information











**Criteria Specification:** *ClinGen Limb Girdle Muscular Dystrophy Expert Panel Specifications to the ACMG/AMP*

Evidence submitted by expert panel

**Limb Girdle Muscular Dystrophy VCEP**

The NM\_000070.3: c.1194-2A>G variant in CAPN3 occurs within the canonical splice acceptor site of intron 9. This variant is predicted to abolish the consensus splice acceptor site, with a SpliceAI score of 0.99, and strengthen two alternative acceptor sites in exon 10 at +13 and +37 (SpliceAI score 0.66 and 0.36). Skipping of exon 10, which is out of frame, would be expected to disrupt the reading frame, leading to nonsense mediated RNA decay in a gene in which loss of function is an established mechanism of disease. Use of either of the alternative acceptor sites would also be expected to disrupt the reading frame (PVS1). This variant has been detected in one individual with features consistent with LGMD, where it was confirmed in trans with a pathogenic variant (c.1524G>A p.(Glu508=), 1.0 pt, ClinVar SCV001423801.2 internal data communication; PM3). This individual had a clinical diagnosis of muscular dystrophy and absent calpain-3 protein expression in skeletal muscle, which is highly specific for CAPN3-related LGMD (PP4\_Strong). In this individual, the variant was identified as a de novo occurrence, and parental relationships were confirmed (PS2\_Supporting). This variant is not found in gnomAD v4.1.0 (PM2\_Supporting). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive limb girdle muscular dystrophy based on the ACMG/AMP criteria applied, as specified by the ClinGen LGMD VCEP (LGMD VCEP specifications version 2.0.0; 10/09/2025): PVS1, PM3, PP4\_Strong, PS2\_Supporting, PM2\_Supporting.

**Met criteria codes**

<b>PM3</b>	 	This variant has been detected in one individual with features consistent with LGMD, where it was confirmed in trans with a pathogenic variant (c.1524G>A p.(Glu508=), 1.0 pt, ClinVar SCV001423801.2 internal data communication; PM3). Nothing in LOVD, no other submitters in ClinVar, no lit citations in ClinVar
<b>PS2_Supporting</b>	 	This variant was identified as a de novo occurrence in one patient meeting criteria for PP4, with confirmed parental relationships (ClinVar SCV001423801.2 internal data communication; PS2_Supporting).
<b>PP4_Strong</b>	 	At least one patient with this variant and a second CAPN3 variant had a clinical diagnosis of muscular dystrophy and absent calpain-3 protein expression in skeletal muscle, which is highly specific for CAPN3-related LGMD (ClinVar SCV001423801.2 internal data communication; PP4_Strong). Illumina case: One patient with severe muscular dystrophy, high CPK levels, achilles tendon retractions, sural muscle hypertrophy, bilateral palpebral ptosis, severe dystrophic pattern on muscle biopsy, Muscle biopsy absent for Calpain protein.
<b>PVS1</b>	 	The NM_000070.3: c.1194-2A>G variant in CAPN3 occurs within the canonical splice acceptor site of intron 9. This variant is predicted to abolish the consensus splice acceptor site, with a SpliceAI score of 0.99, and strengthen two alternative acceptor sites in exon 10 at +13 and +37 (SpliceAI score 0.66 and 0.36). Skipping of exon 10, which is out of frame, would be expected to disrupt the reading frame, leading to nonsense mediated RNA decay in a gene in which loss of function is an established mechanism of disease. Use of either of the alternative acceptor sites would also be expected to disrupt the reading frame (PVS1). SpliceAI: acceptor loss: 0.99, skipping of exon 10 is out of frame, occurs in 35 samples in SpliceVault acceptor gain at +13: 0.66 (ref 0): out of frame, occurs in 6 samples in SpliceVault acceptor gain at +37: 0.36 (ref 0.01): out of frame, occurs in 8 samples in SpliceVault
<b>PM2_Supporting</b>	 	Variant not found in gnomAD v 4.1.0 (PM2_Supporting).

### Not Met criteria codes

**PS1**



c.1194-2del has same predicted splice effects with similar prediction scores; if LP, PS1 N/A but if P, PS1 (per Walker et al. guidelines)

### Curation History [↗](#)

Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.